Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance ...

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

Mitolyn is a natural weight loss supplement designed to target a hidden cause of stubborn fat—poor mitochondrial health. Based on Harvard research ...

Cognition Therapeutics surges 35% after a positive FDA meeting for Alzheimer’s drug zervimesine. Read more here.

Approval was based on results from the Phase IIIb TRAILBLAZER-ALZ 6 trial, which showed that Kisunla achieved comparable ...

The FDA has approved a label update for Eli Lilly’s Kisunla, an Alzheimer’s treatment, by modifying the recommended dosing schedule for adults with early symptomatic Alzheimer’s disease. The update ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

US FDA approves updated label for Eli Lilly's Kisunla with new dosing in early symptomatic Alzheimer's disease: Indianapolis Thursday, July 10, 2025, 14:00 Hrs [IST] Eli Lilly and ...

Indianapolis: Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for a label update ...